“We had a very strong second quarter and delivered on our prior guidance for both revenue growth and gross margin expansion sequentially compared to the first quarter of 2021. Our growth reflected increased sales of allergy diagnostic kits and immunotherapy treatments, expanding our customer base, and strong execution by our team. We leveraged our deep applications expertise and industry relationships. Our targeted solutions and compelling customer value proposition are clearly resonating with independent medical practitioners. In addition, we remain disciplined allocators of capital with the increase in our second quarter cash balance allowing us to further opportunistically invest in driving our growth strategy and anticipate continued revenue growth in the third quarter,” said Troy Grogan, CEO of USA Equities Corp.

“Today’s announcement is further evidence of our continued progress and momentum as we expand our independent medical provider practice network. The growing interest in AllergiEnd®’s allergy diagnostic services and allergen immunotherapy products reflects the attractiveness of our value-based tools to proactively address chronic disease, provide preventive care as well as enable the broad market of general practitioner physicians to broaden their practices and revenue base,” said Troy Grogan, CEO of USA Equities Corp.

“We made excellent progress executing on our financial and strategic priorities in the first quarter of 2021,” stated USAQ Chief Executive Officer Troy Grogan. “On a sequential basis, our revenue more than doubled to approximately $304,000, while gross margin improved 370 basis points to 43.9%. This growth is due to increased sales of allergy diagnostic kits and immunotherapy treatments as well as expansion of our customer base We also saw continued momentum in April, and currently expect an increase in revenue and gross margin in the second quarter of 2021.”

USA Equities Corp. announced that it has engaged several firms in the area of corporate communications, investment community outreach, and strategic partnering to further expand the Company’s visibility and level of investor and corporate community engagement.

WEST PALM BEACH, FL, Feb. 23, 2021 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) announced today that it has appointed Mr. Mike Mangus to its advisory and physician network development team. Mike will provide strategic guidance in the expansion of the Company’s physician network in conjunction with the Company’s automated cloud-based SaaS digital medicine and virtual care system.

WEST PALM BEACH, FL, Feb. 17, 2021 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) announced today its newest appointments to the medical and scientific advisory board. Joining the team of leading researchers and medical experts is Björn Herman, MD, FACS, who serves as the Assistant Professor of Otolaryngology at the University of Miami Miller School of Medicine; Frank Lichtenberger, MD, Ph.D., Board Certified Internist, and Allergy Immunologist; Juan Escobar, MD. Internal Medicine; and Fredric W. Pullen, II MD, FACS, Professor, vol., Otolaryngology, at the University of Miami, Miller School of Medicine.

USA Equities Corp CEO, Troy Grogan, was featured on the latest episode of OTCQB Podcast, Advisor Insights. Listen in as he shares the ways that MPI differentiates itself from competitors in the emerging virtual healthcare space.

WEST PALM BEACH, FL, Dec. 30, 2020 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) (the “Company,” “we,” or “our”) announced today that its revenues for the fourth quarter of 2020 would be approximately $120,000 and that its revenues would exceed $300,000 in the first quarter of 2021.

Despite the uncertainty surrounding the COVID-19 vaccine, physicians can alleviate the patient's worry by providing an allergy test ahead of vaccination. Patients should explore allergy testing ahead of vaccination. Often someone discovers that they are allergic to something - only after being exposed to an allergen and experiencing the negative effects.

USA Equities Corp. (OTCQB: USAQ) CEO Troy Grogan tells Proactive the group is gaining traction with its cloud-based software as a Medical Device system QHSLab, together with increased revenue growth from its distribution agreement with MedScience Research Group.

WEST PALM BEACH, FL, Oct. 26, 2020 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) and its wholly-owned subsidiary Medical Practice Income, announced an exclusive distribution agreement with MedScience Research Group, Inc. today. MedScience granted the Company an exclusive right to distribute its allergy diagnostics and allergen immunotherapy system and related components to physicians who are not allergy specialists.

Listen in as USA Equities Corp CEO Troy Grogan discusses USAQ’s unique value and position.

United States Equities Corp (Stock symbol USAQ) has been identified by Litchfield Hills Research as an "attractive" opportunity for those interested in the digital medicine space. With stocks currently trading under $1, the research group rates USAQ as a BUY with a target price of $5 per share.